Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.35 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | SCN1A | P35498 | 2/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.36 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12844852 | 0.89 | CYP1A2 (0.61) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 | |
| SCHEMBL10386552 | 0.80 | CYP1A2 (0.76) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 | |
| SCHEMBL10387995 | 0.80 | CYP1A2 (0.76) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 | |
| SCHEMBL10804708 | 0.78 | CYP1A2 (0.73) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 | |
| SCHEMBL865680 | 0.78 | CYP1A2 (0.73) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 | |
| SCHEMBL23493022 | 0.78 | CYP1A2 (0.73) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 | |
| SCHEMBL29502067 | 0.78 | CYP1A2 (0.73) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 | |
| SCHEMBL23493019 | 0.78 | CYP1A2 (0.73) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 | |
| SCHEMBL23493031 | 0.78 | CYP1A2 (0.73) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 | |
| SCHEMBL3358175 | 0.78 | CYP1A2 (0.73) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1851215-B1 | WATER-SOLUBLE TETRAZOLIUM SALTS | BAYER HEALTHCARE LLC (US) | 2013-12-18 | — | — | EP | disclosed |
| US-7897331-B2 | Process of using a tetrazolium salt | BAYER HEALTHCARE LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100255506-A1 | PROCESS OF USING A TETRAZOLIUM SALT | BAYER HEALTHCARE LLC (US) | 2010-10-07 | — | — | US | disclosed |
| US-7767822-B2 | Water-soluble tetrazolium salts | BAYER HEALTHCARE LLC (US) | 2010-08-03 | — | — | US | disclosed |
| US-20080125471-A1 | Water-Soluble Tetrazolium Salts | ASCENSIA DIABETES CARE HOLDINGS AG (CH) | 2008-05-29 | — | — | US | disclosed |
| EP-1851215-A1 | WATER-SOLUBLE TETRAZOLIUM SALTS | Bayer Healthcare, LLC (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006076619-A1 | WATER-SOLUBLE TETRAZOLIUM SALTS | BAYER HEALTHCARE LLC (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125471-A1 | Water-Soluble Tetrazolium Salts | TST, AASDHPPT, APRT | CHRM2 4713/4885CHRM1 4376/4885ACHE 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.